vx-702
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00205478)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Also potent inhibitor of MAPK11
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F- Mol. weight
- 404.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1090090 ↗
Also known as
- kvk702
- kvk 702
- kvk-702
- vx 702
- vx-702
- vx-702
- vx-702
- vx-702
- vx-702
- vx702 cpd
- vx805 cpd
- vx 850
- vx-850
- vx 954
- vx-954
- vx954 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00395577 | Phase 2 | Nov 1, 2006 | Vertex |
| NCT00205478 | Phase 2 | Jun 1, 2005 | Vertex |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 2 | 2 | 1 | 2005 |
1 organizations
Page 1 / 1